SAMD13 and hepatocellular carcinoma: Since the biological role of SAMD13 enriches the “cell cycle” and “nucleic acid metabolic process”, we further examined the chemosensitivity to cisplatin, doxorubicin, sorafenib, and JNJ-28841072 which have been shown to potently inhibit the cell cycle used for the treatment of HCC from three independent GEO data set, including GSE54175 (identification of chemo-resistant genes in human metastatic HCC), GSE121153 (sorafenib-resistant HCC), GSE125180 (doxorubicin-resistant HCC), and GSE93595 (anti-angiogenic drug resistant HCC).